Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04670679 · ClinicalTrials.gov registry record · Phase 1

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Erasca.

Active
Registry status
Phase 1
Development phase
200
Enrollment target
14
Study locations

NCT04670679 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Erasca. The registered enrollment target is 200 participants, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower). The trial reports 14 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04670679, a Phase 1 study of Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Erasca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
14
Study locations

Study Summary

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG Pembrolizumab
  • DRUG Cetuximab
  • DRUG ERAS-601

Study Locations (14)

Texas

  • Mary Crowley Cancer Research - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • Sarah Cannon Research Institute (Florida Cancer Specialists) - Sarasota

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University - St Louis

Nevada

  • Comprehensive Cancer Centers of Nevada - Henderson

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-12-15
Est. Completion 2026-02
Phase Phase 1

Sponsor

Erasca

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04670679

The ClinicalTrials.gov registry entry for NCT04670679 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (12% lower). The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT04670679 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Texas, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT04670679 about?

NCT04670679 is a clinical study titled "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors". * To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ...

What is the current status of trial NCT04670679?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-12-15. Estimated completion is 2026-02.

What conditions does trial NCT04670679 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT04670679?

The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), ERAS-601 (DRUG).

Who is sponsoring clinical trial NCT04670679?

This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04670679 being conducted?

This trial has 14 study locations across Alabama, Florida, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.